Although previous studies suggested the association of CD2+, CD34+, and CD56+ phenotypes with poor APL outcomes, the multivariate analysis has demonstrated that WBC count before treatment is the only known independent risk factor that predicts prognosis for this disease in this study population. Here, CD34 is linked to acute promyelocytic leukemia.